Advertisement

Infection

, Volume 46, Issue 1, pp 77–82 | Cite as

Effectiveness of kidney transplantation in HIV-infected recipients under combination antiretroviral therapy: a single-cohort experience (Brescia, Northern Italy)

  • Ilaria IzzoEmail author
  • Salvatore Casari
  • Nicola Bossini
  • Maria Antonia Forleo
  • Silvio Sandrini
  • Emanuele Focà
  • Nigritella Brianese
  • Giulia Zambolin
  • Claudia Chirico
  • Giovanni Cancarini
  • Francesco Castelli
Original Paper

Abstract

Purpose

Kidney transplantation was recently introduced for the treatment of end stage renal disease (ESRD) in HIV-infected patients. We report the results of the first 28 procedures at our centre.

Methods

A retrospective study was conducted on HIV-infected patients evaluated for kidney transplantation between January 2005 and October 2016. Patients were selected and monitored by the kidney transplantation and infectious diseases teams, according to the national protocol.

Results

60 patients were evaluated; 32 entered the list and 28 were transplanted. Median CD4+ count was 337 cell/μL at transplantation and 399 cell/μL 12 months thereafter. HIV RNA was undetectable at transplantation in 27/28 patients and became undetectable within 24 weeks in the only patient starting antiretroviral combination therapy (cART) after surgery. Four patients experienced virological failure, but reached again undetectability after cART regimen change. At last available point of follow-up (median 126.1 weeks), HIV RNA was undetectable in all patients. Three patients experienced AIDS-defining events. We observed a cumulative number of 19 acute rejections in 16 patients (median time from transplantation to first rejection 5.2 weeks). Survival rate was 82.1%. To avoid pharmacokinetics (PK) interactions, cART regimen was changed from a protease inhibitor (PI)/non-nucleoside reverse transcriptase inhibitor (NNRTI)-based to an integrase inhibitor (InSTI)-based regimen in 11/20 alive patients with functioning graft.

Conclusions

Kidney transplantation appears to be safe in HIV-infected patients carefully selected. As previously reported, we observed a high incidence of acute rejection. We expect that the recent implementation of the immunosuppressive protocols will allow a better immunologic control. Moreover, the introduction of InSTI permits a better strategy of cART, with lower incidence of PK interactions with immunosuppressive drugs.

Keywords

HIV Kidney transplantation Combination antiretroviral therapy 

Notes

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

  1. 1.
    Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14:195–207.CrossRefPubMedGoogle Scholar
  2. 2.
    Smith CJ, Ryom L, Weber R, D: A: D Study Group, et al. Trends in underlying cause of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of US transplant centres. Transplantation. 1998;65:1187–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Miro JM, Aguero F, Laguno M, et al. Liver transplantation in HIV/hepatitis coinfection. J HIV Ther. 2007;12:24–35.PubMedGoogle Scholar
  5. 5.
    Trullas JC, Cofan F, Tuset M, Ricart MJ, Brunet M, Cervera C, Manzardo C, López-Dieguez M, Oppenheimer F, Moreno A, Campistol JM, Miro JM. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int. 2011;79:825–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Nashar K, Sureshkumar KK. Update on kidney transplantation in human immunodeficiency virus infected recipients. World J Nephrol. 2016;5:300–7.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Protocollo del Centro Nazionale Trapianti-18 giugno 2004. Programma pilota di terapia sostitutiva con trapianto da donatore cadavere dell’insufficienza renale cronica in soggetti con infezione da HIV. http://www.trapianti.salute.gov.it/imgs/C_17_normativa_6_allegato.pdf. Accessed 17 Jan 2016.
  8. 8.
    Bossini N, Sandrini S, Casari S, Tardanico R, Maffeis R, Setti G, Valerio F, Forleo MA, Nodari F, Cancarini G. Kidney transplantation in HIV-positive patients treated with a steroid-free immunosuppressive regimen. Transpl Int. 2014;27:1050–9.CrossRefPubMedGoogle Scholar
  9. 9.
    http://www.agenziafarmaco.gov.it/it. Accessed 20 Dec 2016.
  10. 10.
    Atta MG, Choi MJ, Longenecker JC, Haymart M, Wu J, Nagajothi N, Racusen LC, Scheel PJ Jr, Brancati FL, Fine DM. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med. 2005;118:1288.CrossRefPubMedGoogle Scholar
  11. 11.
    Morabito V, Grossi P, Lombardini L, et al. Solid organ transplantation in HIV+ recipients: Italian experience. Transpl Proc. 2016;48:4242–430.Google Scholar
  12. 12.
    Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363:2004–14.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Landin L, Rodriguez-Perez JC, Garcia-Bello MA, Cavadas PC, Thione A, Nthumba P, Blanes M, Ibañez J. Kidney transplants in HIV-positive recipients under HAART. A comprehensive review and meta-analysis of 12 series. Nephrol Dial Transplant. 2010;25:3106–15.CrossRefPubMedGoogle Scholar
  14. 14.
    Gathogo EN, Hamzah L, Hilton R, Marshall N, Ashley C, Harber M, Levy JB, Jones R, Boffito M, Khoo SH, Drage M, Bhagani S, Post FA. Kidney transplantation in HIV-positive adults: the UK experience. Int J STD AIDS. 2014;25:57–66.CrossRefPubMedGoogle Scholar
  15. 15.
    Waki K, Sugawara Y. Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572). Biosci Trends. 2011;5:189–91.CrossRefPubMedGoogle Scholar
  16. 16.
    Azar MM, Malinis MF, Moss J, Formica RN, Villanueva MS. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. Int J STD AIDS. 2017;28:447–58.CrossRefPubMedGoogle Scholar
  17. 17.
    Touzot M, Pillebout E, Matignon M, Tricot L, Viard JP, Rondeau E, Legendre C, Glotz D, Delahousse M, Lang P, Peraldi MN. Renal transplantation in HIV-infected patients: the Paris experience. Am J Transplant. 2010;10:2263–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Ilaria Izzo
    • 1
    Email author
  • Salvatore Casari
    • 1
  • Nicola Bossini
    • 2
  • Maria Antonia Forleo
    • 1
  • Silvio Sandrini
    • 2
  • Emanuele Focà
    • 1
  • Nigritella Brianese
    • 1
  • Giulia Zambolin
    • 1
  • Claudia Chirico
    • 1
  • Giovanni Cancarini
    • 2
  • Francesco Castelli
    • 1
  1. 1.University Department of Infectious and Tropical DiseasesUniversity of Brescia and Spedali Civili General HospitalBresciaItaly
  2. 2.Division of NephrologyUniversity of Brescia and Spedali Civili General HospitalBresciaItaly

Personalised recommendations